It was reported that cRGD-modified iLNPs could interact with HepG2 cells more efficiently than unmodified counterparts, which dramatically enhanced antitumor efficacy of PLK1 siRNA in tumor-bearing mice (Guo et al.2021). The gene discussed is PLK1; the disease is neoplasm.